Your browser doesn't support javascript.
loading
DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.
Li, Meng-yuan; Lv, Yong-cong; Tong, Lin-jiang; Peng, Ting; Qu, Rong; Zhang, Tao; Sun, Yi-ming; Chen, Yi; Wei, Li-xin; Geng, Mei-yu; Duan, Wen-hu; Xie, Hua; Ding, Jian.
Affiliation
  • Li MY; Pharmacology and Safety Evaluation Key Laboratory of Tibetan Medicine in Qinghai Province, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining 810008, China.
  • Lv YC; Division of Antitumor Pharmacology and Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Tong LJ; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Peng T; Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Qu R; Division of Antitumor Pharmacology and Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Zhang T; Division of Antitumor Pharmacology and Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Sun YM; Division of Antitumor Pharmacology and Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Chen Y; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Wei LX; University of Chinese Academy of Sciences, Beijing 100049, China.
  • Geng MY; Shanghai Tech University, Shanghai 200120, China.
  • Duan WH; Division of Antitumor Pharmacology and Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Xie H; Division of Antitumor Pharmacology and Department of Medicinal Chemistry, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
  • Ding J; Pharmacology and Safety Evaluation Key Laboratory of Tibetan Medicine in Qinghai Province, Northwest Institute of Plateau Biology, Chinese Academy of Sciences, Xining 810008, China.
Acta Pharmacol Sin ; 37(3): 398-407, 2016 Mar.
Article in En | MEDLINE | ID: mdl-26806300
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrimidines / Glioblastoma / Angiogenesis Inhibitors / Receptors, Vascular Endothelial Growth Factor Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Acta Pharmacol Sin Journal subject: FARMACOLOGIA Year: 2016 Type: Article Affiliation country: China
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrimidines / Glioblastoma / Angiogenesis Inhibitors / Receptors, Vascular Endothelial Growth Factor Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Acta Pharmacol Sin Journal subject: FARMACOLOGIA Year: 2016 Type: Article Affiliation country: China